vs
Amphastar Pharmaceuticals, Inc.（AMPH）与IMPINJ INC（PI）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是IMPINJ INC的2.5倍（$183.1M vs $74.3M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 11.2%，领先2.1%），IMPINJ INC同比增速更快（-0.0% vs -1.8%），Amphastar Pharmaceuticals, Inc.自由现金流更多（$24.6M vs $2.2M），过去两年Amphastar Pharmaceuticals, Inc.的营收复合增速更高（3.2% vs -14.9%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Impinj Inc.是一家美国射频识别（RFID）设备及软件提供商，成立于2000年，总部位于华盛顿州西雅图，源自加州理工学院Carver Mead与Chris Diorio的研究成果。公司主营EPC Class 1 Gen 2无源超高频RFID芯片、读写器、读写器芯片、天线，以及芯片编码、业务数据采集相关的软件应用，为各行业RFID应用提供全链路产品支持。
AMPH vs PI — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $74.3M |
| 净利润 | $24.4M | $8.3M |
| 毛利率 | 46.8% | 49.1% |
| 营业利润率 | 19.4% | 30.5% |
| 净利率 | 13.3% | 11.2% |
| 营收同比 | -1.8% | -0.0% |
| 净利润同比 | -35.7% | — |
| 每股收益（稀释后） | $0.51 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $74.3M | ||
| Q4 25 | $183.1M | $92.8M | ||
| Q3 25 | $191.8M | $96.1M | ||
| Q2 25 | $174.4M | $97.9M | ||
| Q1 25 | $170.5M | $74.3M | ||
| Q4 24 | $186.5M | $91.6M | ||
| Q3 24 | $191.2M | $95.2M | ||
| Q2 24 | $182.4M | $102.5M |
| Q1 26 | — | $8.3M | ||
| Q4 25 | $24.4M | $-1.1M | ||
| Q3 25 | $17.4M | $-12.8M | ||
| Q2 25 | $31.0M | $11.6M | ||
| Q1 25 | $25.3M | $-8.5M | ||
| Q4 24 | $38.0M | $-2.7M | ||
| Q3 24 | $40.4M | $221.0K | ||
| Q2 24 | $37.9M | $10.0M |
| Q1 26 | — | 49.1% | ||
| Q4 25 | 46.8% | 51.8% | ||
| Q3 25 | 51.4% | 50.3% | ||
| Q2 25 | 49.6% | 57.8% | ||
| Q1 25 | 50.0% | 49.4% | ||
| Q4 24 | 46.5% | 50.5% | ||
| Q3 24 | 53.3% | 50.0% | ||
| Q2 24 | 52.2% | 56.1% |
| Q1 26 | — | 30.5% | ||
| Q4 25 | 19.4% | -2.9% | ||
| Q3 25 | 13.2% | 0.7% | ||
| Q2 25 | 24.2% | 11.1% | ||
| Q1 25 | 21.9% | -12.9% | ||
| Q4 24 | 24.2% | -3.9% | ||
| Q3 24 | 29.8% | -0.8% | ||
| Q2 24 | 30.3% | 8.8% |
| Q1 26 | — | 11.2% | ||
| Q4 25 | 13.3% | -1.2% | ||
| Q3 25 | 9.0% | -13.3% | ||
| Q2 25 | 17.8% | 11.8% | ||
| Q1 25 | 14.8% | -11.4% | ||
| Q4 24 | 20.4% | -2.9% | ||
| Q3 24 | 21.1% | 0.2% | ||
| Q2 24 | 20.8% | 9.7% |
| Q1 26 | — | $0.14 | ||
| Q4 25 | $0.51 | $-0.02 | ||
| Q3 25 | $0.37 | $-0.44 | ||
| Q2 25 | $0.64 | $0.39 | ||
| Q1 25 | $0.51 | $-0.30 | ||
| Q4 24 | $0.74 | $-0.06 | ||
| Q3 24 | $0.78 | $0.01 | ||
| Q2 24 | $0.73 | $0.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $131.8M |
| 总债务越低越好 | $608.7M | $241.5M |
| 股东权益账面价值 | $788.8M | — |
| 总资产 | $1.6B | $502.5M |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
| Q1 26 | — | $131.8M | ||
| Q4 25 | $282.8M | $175.3M | ||
| Q3 25 | $276.2M | $190.1M | ||
| Q2 25 | $231.8M | $193.2M | ||
| Q1 25 | $236.9M | $147.9M | ||
| Q4 24 | $221.6M | $164.7M | ||
| Q3 24 | $250.5M | $170.3M | ||
| Q2 24 | $217.8M | $220.2M |
| Q1 26 | — | $241.5M | ||
| Q4 25 | $608.7M | $280.9M | ||
| Q3 25 | $608.6M | $280.4M | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $283.5M | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | $788.8M | $209.2M | ||
| Q3 25 | $776.7M | $195.0M | ||
| Q2 25 | $757.5M | $187.7M | ||
| Q1 25 | $751.3M | $160.6M | ||
| Q4 24 | $732.3M | $149.9M | ||
| Q3 24 | $727.7M | $136.1M | ||
| Q2 24 | $713.3M | $117.0M |
| Q1 26 | — | $502.5M | ||
| Q4 25 | $1.6B | $545.2M | ||
| Q3 25 | $1.7B | $516.5M | ||
| Q2 25 | $1.6B | $508.8M | ||
| Q1 25 | $1.6B | $479.8M | ||
| Q4 24 | $1.6B | $489.1M | ||
| Q3 24 | $1.5B | $476.4M | ||
| Q2 24 | $1.5B | $446.1M |
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | 1.34× | ||
| Q3 25 | 0.78× | 1.44× | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 1.89× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | — |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $2.2M |
| 自由现金流率自由现金流/营收 | 13.4% | 3.0% |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | $61.1M |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $15.1M | ||
| Q3 25 | $52.6M | $20.9M | ||
| Q2 25 | $35.6M | $33.9M | ||
| Q1 25 | $35.1M | $-11.1M | ||
| Q4 24 | $29.0M | $12.6M | ||
| Q3 24 | $60.0M | $10.1M | ||
| Q2 24 | $69.1M | $45.5M |
| Q1 26 | — | $2.2M | ||
| Q4 25 | $24.6M | $13.6M | ||
| Q3 25 | $47.2M | $18.0M | ||
| Q2 25 | $25.0M | $27.3M | ||
| Q1 25 | $24.4M | $-13.0M | ||
| Q4 24 | $16.6M | $8.5M | ||
| Q3 24 | $46.2M | $4.7M | ||
| Q2 24 | $63.1M | $44.1M |
| Q1 26 | — | 3.0% | ||
| Q4 25 | 13.4% | 14.7% | ||
| Q3 25 | 24.6% | 18.7% | ||
| Q2 25 | 14.3% | 27.9% | ||
| Q1 25 | 14.3% | -17.5% | ||
| Q4 24 | 8.9% | 9.3% | ||
| Q3 24 | 24.1% | 4.9% | ||
| Q2 24 | 34.6% | 43.0% |
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 1.6% | ||
| Q3 25 | 2.8% | 3.1% | ||
| Q2 25 | 6.1% | 6.7% | ||
| Q1 25 | 6.3% | 2.5% | ||
| Q4 24 | 6.7% | 4.5% | ||
| Q3 24 | 7.2% | 5.7% | ||
| Q2 24 | 3.3% | 1.3% |
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | 2.93× | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 45.56× | ||
| Q2 24 | 1.82× | 4.56× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PI
暂无分部数据
